Highlights Order placed for 20,000 units of the Company’s lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release. Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website. Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company’s May 19, 2026 news release. Vancouver, British Columbia–(Newsfile Corp. – May 26, 2026) – The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “BPC”), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its BPC-157 transdermal patch (the “Patch”), the Company’s lead product candidate. The order is intended to support the Patch’s planned commercial release.
This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.
Brief Summary
The Precision Peptide Company Inc. has announced a significant order of 20,000 BPC-157 transdermal patches, aimed at ensuring a successful commercial launch. The BPC-157 patches are expected to deliver key benefits for wellness enthusiasts, potentially transforming the market.
- 20,000 patches ordered to support launch
- Each patch delivers 2 mg of BPC-157
- Commercial release anticipated by June 2026
- Order confirms commitment to quality with 95.5% purity
Why it matters: This move signifies a critical step towards the company’s goal of innovating peptide delivery systems and enhancing wellness, captivating attention from investors and consumers alike.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Newsfile Corp on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.